Prevalence of Cardiovascular Drugs Among Pregnant Women in Sudan


  • Haj Elamin. E. Azhari, Siddiqa M. A. Hamza, Mohammed. R.R, H. E. Omer, A. M. Iman, Entesar Mohammed Abdulla Tabein, Hadeil M. E. Idris



Pregnant Women, Cardiovascular Medications, Hypertension, Methyldopa


Background: Pregnant women with heart disease present multiple medical dilemmas. Pregnancy-related physiological changes impair the heart's ability to respond to pathological processes such as hypertension and heart failure.

Aim: The current study's aim is to elicit data on cardiovascular medication use during pregnancy.

Methods: This is a descriptive, retrospective, cross-sectional, hospital-based study, carried out in Military Hospitals and Khartoum Teaching Hospital, in Sudan. A data collection form was utilized to gather information from 650 patient files of pregnant women.

Results: 650 subjects met the study criteria; 7% of women (N=46) were dispensed cardiovascular medications, the consumption being significantly higher in the third trimester (7-9 months) in 78.26% (p<0.05). The most common cardiovascular drugs dispensed were Methyldopa (N=26, 4.0%), Heparin (N=9, 1.3%), Nifedipine (N=7, 1.0%), Hydralazine (N=2, 0.3%) and Diazepam (N=2, 0.3%). Methyldopa is the commonest in the all trimesters - first (1-3 months) (N=2, 0.3%), second (4-6 months) (N=4, 0.6%) and third (7-9 months) (N=20, 3.0%). Nifedipine and Diazepam were used only in the third trimester.

Conclusions: There are many clinical situations requiring cardiovascular medications in pregnancy. Thus, it is necessary to conduct frequent health educational programs educating pregnant women about the risk factors for pregnancy-induced cardiovascular disease, and proper use of medication.